A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

Status: Recruiting

Location: See all (3) locations...

Intervention Type: Biological

Study Type: Interventional

Study Phase: Phase 1/Phase 2

SUMMARY

To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

• Voluntary provision of written informed consent and ability to comply with protocol requirements.

• Age ≥18 years, male or female.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

• Confirmed diagnosis of immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed autoimmune hemolytic anemia (mAIHA) or Evans Syndrome.

• Relapsed or refractory autoimmune hemolytic anemia.

Locations

Other Locations

China

Heping Hospital Affiliated to Changzhi Medical College

RECRUITING

Changzhi

Blood Disease Hospital, Chinese Academy of Medical Sciences

RECRUITING

Tianjin

Henan Cancer Hospital

RECRUITING